Stock NVNO ENVVENO MEDICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News enVVeno Medical Corporation

Equities

NVNO

US29415J1060

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-15 EDT 		5-day change 1st Jan Change
5 USD 0.00% Intraday chart for enVVeno Medical Corporation -1.96% -2.72%
05-08 EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-16 EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EnVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
AQ
New Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the 46th Annual Charing Cross Symposium on April 24, 2024
AQ
EnVVeno Medical Corporation Announces Additional Topline Efficacy Data from the VenoValve U.S. Pivotal Trial to Be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
CI
EnVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
AQ
EnVVeno Medical : Corporate Presentation
PU
EnVVeno Medical Corporation Appoints Andrew Cormack as Its Chief Commercial Officer
CI
EnVVeno Medical : Corporate Presentation
PU
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
AQ
EnVVeno Announces Positive Topline Efficacy Data for VenoValve US Pivotal Trial
MT
EnVVeno Medical Corporation Announces the Presentation of Positive Topline Efficacy Data Showing Significant Clinical Improvement from the Savve U.S. Pivotal Trial for the Venovalve
CI
EnVVeno Medical : Corporate Presentation
PU
EnVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
AQ
EnVVeno Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Topline Efficacy Data from the enVVeno Medical VenoValve Pivotal Trial to be presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
AQ
EnVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
AQ
EnVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
AQ
EnVVeno Medical Corporation Presents Positive Preliminary Device Related Material Adverse Event Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
CI
EnVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVNO Stock
  4. News enVVeno Medical Corporation
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**BENEFIT NOW**0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW